Resumen
INTRODUCCIÓN:La vitamina D actúa en múltiples tejidos y procesos fisiológicos. El objetivo del estudio fue determinar los niveles de vitamina D en pacientes con epilepsia tratados con anticonvulsivantes.
MATERIAL Y MÉTODOS:Estudio observacional, descriptivo, de corte transversal en pacientes con diagnóstico de epilepsia que asistieron al servicio de consulta externa de un hospital de tercer nivel de atención de Neiva, Colombia, entre marzo y octubre de 2018. Se midieron los niveles séricos de vitamina D, paratohormona, albúmina y calcio.
RESULTADOS:Una muestra de 90 pacientes. La mediana de edad fue de 36,5 (rango 18-81 años), 46 (51,1%) presentaron niveles bajos de vitamina D (38,8% en rango de insuficiencia y 12,2% rango de deficiencia). Se documentó asociación entre el sexo femenino y niveles insuficientes y deficientes de vitamina D, el no realizar ejercicio con niveles insuficientes de vitamina D, la exposición diaria al sol menor de 15 minutos y el no realizar caminata con niveles deficientes de vitamina D. El déficit de vitamina D se asoció con incremento de los niveles de paratohormona, mediana 103,9 pg/ml (rango 30,7-182,9 pg/ml, P <0,01). No se encontraron diferencias entre los niveles de vitamina D y el uso de monoterapia, politerapia, ni con la utilización fármacos inductores enzimáticos.
CONCLUSIONES:En pacientes con terapia anticonvulsivante es frecuente encontrar niveles insuficientes/ deficientes de vitamina D aunque no se encontró asociación con el uso de monoterapia, politerapia o inductores enzimáticos hepáticos.
Citas
Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, et al. Skeletal and extraskeletal actions of vitamin d: current evidence and outstanding questions. Endocr Rev. 2018;40(4):1109-51. doi:10.1210/er.2018-00126.
Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JPA. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ. 2014;348:g2035. doi:10.1136/bmj.g2035.
Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006;96:252-261. doi: 10.2105/AJPH.2004.045260.
Vaughan-Shaw PG, O'Sullivan F, Farrington SM, Theodoratou E, Campbell H, Dunlop MG, et al. The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis. Br J Cancer. 2017;116(8):1092-110. doi: 10.1038/bjc.2017.44.
Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol. 2012;109(3):359-63. doi: 10.1016/j.amjcard.2011.09.020.
Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33-44. doi: 10.1056/NEJMoa1809944.
Scragg R, Stewart AW, Waayer D, Lawes CMM, Toop L, Sluyter J, et al. Effect of monthly high-dose vitamin d supplementation on cardiovascular disease in the vitamin D assessment study : a randomized clinical trial. JAMA Cardiol. 2017;2(6):608-16. doi: 10.1001/jamacardio.2017.0175.
Hollo A, Clemens Z, Lakatos P. Epilepsy and vitamin D. Int J Neurosci. 2014;124(6):387-93. doi: 10.3109/00207454.2013.847836.
Navarro Mendoza E-P, Tejada Marín J-W, Carrillo DC, Guzmán GE, Arango LG. Prevalencia de la insuficiencia de vitamina D en pacientes con osteoporosis. Rev Colomb Reumatol. 2016;23(1):17-23. doi: 10.1016/j.rcreu.2015.12.006.
Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem?. J Steroid Biochem Mol Biol. 2014;144 Pt A:138-45. doi: 10.1016/j.jsbmb.2013.11.003.
Mithal A, Wahl DA, Bonjour J-P, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20(11):1807-20. doi: 10.1007/s00198-009-0954-6.
Hansen KE, Johnson MG. An update on vitamin D for clinicians. Curr Opin Endocrinol Diabetes Obes. 2016;23(6):440-4. doi: 10.1097/MED.0000000000000288.
Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res. 2011;31(1):48-54. doi: 10.1016/j.nutres.2010.12.001.
Quintana Duque M, Toro C, Restrepo J. Vitamina D en America Latina. Rev Metab Óseo Miner. 2007;5:403-10.
Tovar AP, Vásquez N, Celemin C. Niveles de vitamina D en pacientes con osteoporosis en la ciudad de Neiva, Huila, Colombia. Revista Colombiana de Endocrinología, Diabetes & Metabolismo 2017;2(3):44-50.
Vásquez-Awad D, Cano-Gutiérrez CA, Gómez-Ortiz A, González MA, Guzmán-Moreno R, Martínez-Reyes JI, et al. Vitamina D. Consenso colombiano de expertos. Medicina (Bogotá). 2017;39(2):140-57.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-30. doi: 10.1210/jc.2011-0385.
Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia. 2004;45(11):1330-7. doi: 10.1111/j.0013-9580.2004.18804.x.
Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia. 2006;47(3):510-5. doi: 10.1111/j.1528-1167.2006.00460.x.
Jette N, Lix LM, Metge CJ, Prior HJ, McChesney J, Leslie WD. Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol. 2011;68(1):107-12. doi: 10.1001/archneurol.2010.341.
Souverein PC, Webb DJ, Petri H, Weil J, Van Staa TP, Egberts T. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia. 2005;46(2):304-10. doi: 10.1111/j.0013-9580.2005.23804.x.
Shen C, Chen F, Zhang Y, Guo Y, Ding M. Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis. Bone. 2014;64:246-53. doi: 10.1016/j.bone.2014.04.018.
Nagarjunakonda S, Amalakanti S, Uppala V, Rajanala L, Athina S. Vitamin D in epilepsy: vitamin D levels in epilepsy patients, patients on antiepileptic drug polytherapy and drug-resistant epilepsy sufferers. Eur J Clin Nutr. 2016;70(1):140-2. doi: 10.1038/ejcn.2015.127.
Ramírez-Jiménez JJ, Alfaro-Velásquez JM. Efecto de los medicamentos antiepilépticos en el metabolismo de la vitamina D y el impacto negativo relacionado al déficit. Med Lab. 2015;21(3-4):131-48.
Menon B, Harinarayan CV. The effect of anti epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism-- a longitudinal study. Seizure. 2010;19(3):153-8. doi: 10.1016/j.seizure.2010.01.006.
Fraser LA, Burneo JG, Fraser JA. Enzyme-inducing antiepileptic drugs and fractures in people with epilepsy: A systematic review Epilepsy Res. 2015;116:59-66. doi: 10.1016/j.eplepsyres.2015.07.003.
Nicholas JM, Ridsdale L, Richardson MP, Grieve AP, Gulliford MC. Fracture risk with use of liver enzyme inducing antiepilep-tic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure. 2013;22(1):37-42. doi: 10.1016/j.seizure.2012.10.002.
Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology. 2008;70(18):1586-93. doi: 10.1212/01.wnl.0000310981.44676.de.
Phabphal K, Geater A, Limapichat K, Sathirapanya P, Setthawatcharawanich S, Leelawattana R. Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy. Epilepsia. 2013;54(6):e94-8. doi: 10.1111/epi.12162.
Teagarden DL, Meador KJ, Loring DW. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res. 2014;108(8):1352-6. doi: 10.1016/j.eplepsyres.2014.06.008.
Gutiérrez-Alvarez AM, Gavilanes AV, Velosa DM. Enfermedad ósea asociada al uso de antiepilépticos: la buscan los neurólogos? Acta Neurol Colomb. 2008;24(4).
Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial. Epilepsia. 2013;54(11):1997-2004. doi: 10.1111/epi.12351.
Fernandez H, Mohammed HT, Patel T. Vitamin D supplementation for bone health in adults with epilepsy: A systematic review. Epilepsia. 2018;59(4):885-96. doi: 10.1111/epi.14015.
Miziak B, Blaszczyk B, Chroscinska-Krawczyk M, Danilkiewicz G, Jagiello-Wojtowicz E, Czuczwar SJ. The problem of osteoporosis in epileptic patients taking antiepileptic drugs. Expert Opin Drug Saf.. 2014;13(7):935-46. doi: 10.1517/14740338.2014.919255.
Fisher RS, Cross JH, D'Souza C, French JA, Haut SR, Higurashi N, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58(4):531-42. doi: 10.1111/epi.13671.
Suljic EM, Mehicevic A, Mahmutbegovic N. Effect of long-term carbamazepine therapy on bone health. Med Arch. 2018;72(4):262-6. doi: 10.5455/medarh.2018.72.262-266.
Jovel CE, Pardo C, Moreno C, Vergara J, Hedmont D, Mejía FS. Demographic and social profile of epilepsy in a vulnerable low-income population in Bogotá, Colombia. 2016;31(8):528-34. doi: 10.1016/j.nrl.2014.10.016. Epub 2014 Dec 15.
Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011;1814(1):186-99. doi: 10.1016/j.bbapap.2010.06.022.
Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav. 2004;5 Suppl 2:S3-15. doi: 10.1016/j.yebeh.2003.11.026.
Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia. 2002;43(12):1488-92. doi: 10.1046/j.1528-1157.2002.13002.x.
Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg. 2010;112(1):1-10. doi: 10.1016/j.clineuro.2009.10.011.
Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364(3):248-54. doi: 10.1056/NEJMc1101911.
Misra A, Aggarwal A, Singh O, Sharma S. Effect of carbamazepine therapy on vitamin D and parathormone in epileptic children. Pediatr Neurol. 2010;43(5):320-4. doi: 10.1016/j.pediatrneurol.2010.05.013.
Greene-Finestone LS, Berger C, de Groh M, Hanley DA, Hidiroglou N, Sarafin K, et al. 25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int. 2011;22(5):1389-99. doi: 10.1007/s00198-010-1362-7.
Suarez-Martinez EB, Perez CM, Cruz SK, Khorsandi S, Chardon C, Ferder L. Importance of vitamin D and vitamin D levels status in Puerto Ricans. J Health Care Poor Underserved. 2013;24(4 Suppl):38-47. doi: 10.1353/hpu.2014.0000.
Ginde AA, Liu MC, Camargo CA, Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169(6):626-32. doi: 10.1001/archinternmed.2008.604.
Tombini M, Palermo A, Assenza G, Pellegrino G, Benvenga A, Campana C, et al. Calcium metabolism serum markers in adult patients with epilepsy and the effect of vitamin D supplementation on seizure control. Seizure. 2018;58:75-81. doi: 10.1016/j.seizure.2018.04.008.
Alshahrani F, Aljohani N. Vitamin D: deficiency, sufficiency and toxicity. Nutrients. 2013;5(9):3605-16. doi: 10.3390/nu5093605.
Cebeci AN, Ekici B. Epilepsy treatment by sacrificing vitamin D. Expert Rev Neurother. 2014;14(5):481-91. doi: 10.1586/14737175.2014.905742.
Harijan P, Khan A, Hussain N. Vitamin D deficiency in children with epilepsy: Do we need to detect and treat it?. J Pediatr Neurosci.2013;8(1):5-10. doi: 10.4103/1817-1745.111413
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.